{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-031795","form_type":"8-K","ticker":"TBPH","cik":"0001583107","company_name":"Theravance Biopharma, Inc.","filed_at":"2026-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.533598+00:00","generated_at":"2026-05-15T09:37:41.806260+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Theravance reports Q4/FY2025 financials; restructuring after Phase 3 failure; strategic review ongoing","bullets":["Q4/FY2025: YUPELRI net sales $266.6M (+12% YoY); triggered $25M milestone.","TRELEGY net sales $3.9B (+12% YoY) triggered $50M milestone; confident in $100M 2026 milestone.","Restructuring after failed Phase 3 CYPRESS study; expects $60-70M annualized cash savings starting Q3 2026.","Cash ~$400M at end Q1 2026; no debt.","Strategic Review Committee accelerating evaluation of alternatives including potential sale of company."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-031795","json":"https://secwatch.observer/filing/0001104659-26-031795.json","markdown":"https://secwatch.observer/filing/0001104659-26-031795.md","text":"https://secwatch.observer/filing/0001104659-26-031795.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583107/000110465926031795/0001104659-26-031795-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583107/000110465926031795/tm269321d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:37:41.806260+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}